SFRP2 and PD-1 immunotherapy combination halts osteosarcoma metastasis in model

(Medical University of South Carolina) In a cancer that has not seen new targeted therapies for over 20 years, MUSC Hollings Cancer Center researcher and oncologist Nancy Klauber-DeMore, M.D., is pioneering new discoveries. Using a combination of personal passion and expertise, Klauber-DeMore shifted her knowledge of the pro-angiogenic protein SFRP2 in breast cancer to address the lack of treatment options for patients with aggressive metastatic osteosarcoma. The results of the combination treatment with SFRP2 and PD-1 antibodies in a preclinical model were published in Cancers.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news